The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.
Jung-Im ShinYingying SangAlexander R ChangStephan C DunningJosef CoreshLesley A InkerElizabeth SelvinShoshana H BallewMorgan E GramsPublished in: Journal of the American Society of Nephrology : JASN (2020)
The metformin label change to an eGFR-based contraindication may have reduced racial and sex disparities in metformin prescription in moderate kidney dysfunction.